Nachu Narasimhan

Narayana (Nachu) Narasimhan, Ph.D., is Senior Vice President, Drug Metabolism & Preclinical Safety at Theseus Pharmaceuticals. Nachu has over 30 years of expertise in Drug metabolism, Bioanalytical disciplines and over 10 years in preclinical safety and clinical pharmacology. He has contributed to the development and approval of abamectin and eprinomectin, two anthelminthic drugs while working at Merck. During his tenure at Bristol-Myers-Squibb, Nachu worked on Entecavir, a HepB drug which was approved. During his employment at ARIAD, Nachu was a key member of the discovery and development teams of three approved oncology drugs, ICLUSIG® (ponatinib), ALUNBRIG® (brigatinib), and EXKIVITY® (mobocertinib), approved for EGFR Exon20 insertion+ NSCLC. Most recently, Nachu served as Vice president for Drug Metabolism and Clinical Pharmacology at Verastem Oncology and worked on the successful approval of Copiktra® (duvelisib) in EU. Nachu received his M.S in Chemistry from Indian Institute of Technology, Chennai, and then completed his Ph.D. in chemistry at Vanderbilt University. Nachu conducted post-doctoral research at the University of Kansas. Nachu has published over 40 articles in peer reviewed journals in the areas of medical chemistry, drug metabolism, and Clinical pharmacology and has authored over 100 technical reports and regulatory submission documents.